Pacira Pharmaceuticals (PCRX)
Pacira Pharmaceuticals Revenue Growth: 102.0%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
PCRX Revenue Growth Rankings
| Overall | 96th percentile | 135 of 4363 |
| Sector | 90th percentile | 42 of 457 in Healthcare |
| Industry | 88th percentile | 2 of 18 in Drug Manufacturers - Major |
PCRX Revenue Growth Range, Past 5 Years
| Minimum | -19.25% | Mar 2011 |
| Maximum | 102.0% | Mar 2012 |
| Average | 36.46% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these PCRX related companies
PCRX News
$AMRN $pcrx Lots of charts showing real accumulation at the EOD today.. Good sign in my opinion
about 2 days ago by turrable
about 2 days ago by turrable
Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
May 29, 6:30AM Business Wire
May 29, 6:30AM Business Wire
Barclays on U.S. Specialty Pharmaceuticals: Model Updates on FRX, MRX, WCRX & PCRX
May 25, 12:32PM Street Insider
May 25, 12:32PM Street Insider
$AMRN and $PCRX are my 2 potential home runs. I can honestly say $PCRX is an absolute game changer in the operative setting.
about 7 days ago by turrable
about 7 days ago by turrable
$PCRX Pacira Pharmaceuticals Inc. To Be Added To NASDAQ Biotechnology Index
about 11 days ago by johnkelly
about 11 days ago by johnkelly
$PCRX going higher...like I said ...game changer in the surgical setting
about 21 days ago by turrable
about 21 days ago by turrable
Oxford Finance Provides $27.5 Million Debt Financing Facility to Pacira Pharmaceuticals
May 10, 1:05PM PR Newswire
May 10, 1:05PM PR Newswire
Pacira Pharmaceuticals, Inc. to Present at Bank of America Merrill Lynch 2012 Health Care Conference
May 10, 6:30AM Business Wire
May 10, 6:30AM Business Wire
Listen to $PCRX Q1 2012 earnings call - live at 09:00 AM, ondemand after - http://stks.co/3jvx
about 23 days ago by earningscast
about 23 days ago by earningscast
Pacira Pharmaceuticals, Inc. Reports First Quarter 2012 Financial Results
May 09, 6:30AM Business Wire
May 09, 6:30AM Business Wire
$PCRX It is one of the best products I have ever used in a surgical setting and anyone that has seen it has adopted it faster than fast
about 23 days ago by turrable
about 23 days ago by turrable
$PCRX some crazy tick after hours....I just continue to buy this and $amrn all day every time they are down
about 23 days ago by turrable
about 23 days ago by turrable
Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2012 Financial Results Webcast and Conference Call
May 02, 6:30AM Business Wire
May 02, 6:30AM Business Wire
@expstocktrader Have you heard of or done any research on Pacira Pharmaceuticals? $PCRX
about 36 days ago by jckund
about 36 days ago by jckund
2012 Economic Outlook - Report Highlights OncoGenex Pharmaceuticals Inc and Pacira Pharmaceuticals Inc
Apr 26, 9:00AM Marketwire
Apr 26, 9:00AM Marketwire
Pacira Pharmaceuticals Announces Full Exercise of Overallotment Option by Underwriters
Apr 25, 9:02AM Benzinga
Apr 25, 9:02AM Benzinga
Pacira Pharmaceuticals, Inc. Announces Full Exercise of Overallotment Option by Underwriters
Apr 25, 9:00AM Business Wire
Apr 25, 9:00AM Business Wire
Pacira Pharmaceuticals Prices Public Offering of 6M Shares Common Stock at $9.75/Share
Apr 12, 9:18AM Benzinga
Apr 12, 9:18AM Benzinga
Pacira Pharma (PCRX) Expects to Price 6M Share Offering at $9.75/Share
Apr 12, 8:27AM Street Insider
Apr 12, 8:27AM Street Insider
Pacira Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Apr 11, 4:00PM Business Wire
Apr 11, 4:00PM Business Wire
Pacira Pharmaceuticals, Inc. Announces Commercial Availability of EXPAREL®
Apr 09, 6:30AM Business Wire
Apr 09, 6:30AM Business Wire
Listen to $PCRX Q4 2011 earnings call - live at 09:00 AM, ondemand after - http://stks.co/35tj
about 66 days ago by earningscast
about 66 days ago by earningscast
$PCRX 2011 Earnings Report at: http://stks.co/35kB Company on track for commercial launch of Exparel in April.
about 66 days ago by abubnic
about 66 days ago by abubnic
$PCRX Earnings CC at 9 am ET. Webcast presentation at: http://stks.co/35k6
about 66 days ago by abubnic
about 66 days ago by abubnic
$PCRX reports Q4 EPS of 72c vs consensus of 54c. Revenue: $4.23M vs consensus of $4.05M.
about 66 days ago by abubnic
about 66 days ago by abubnic
$PCRX forms bearish "Continuation Wedge" chart pattern. http://stks.co/2hZu
about 86 days ago by RecogniaEvents
about 86 days ago by RecogniaEvents
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| PCRX | 10.62 | -0.05 | -0.47% | 271.12M |
| PCP | 166.21 | -0.41 | -0.25% | 24.19B |
| PCOM | 11.27 | +0.05 | +0.45% | 169.09M |
| PCN | 16.19 | +0.09 | +0.56% | |
| PCM | 10.94 | -0.03 | -0.27% | |
| PCLN | 625.49 | -12.27 | -1.92% | 31.76B |
| PBY | 9.28 | +0.39 | +4.39% | 468.95M |
| PBTH | 5.09 | +0.07 | +1.39% | 273.79M |
| PBT | 17.64 | -0.45 | -2.49% | 843.17M |
| PBSK | 12.07 | +0.00 | +0.00% |
